The products of in vivo covalent binding of activated aflatoxin B1 (AFB1) to DNA have been investigated in rats. The principal covalent product formed in liver DNA of rats treated with AFB1 has been identified as 2,3-dihydro-2-(N7-guanyl)3hydroxy-aflatoxin B1. This compound was isolated from the liver DNA of rats dosed with AFB1 (2.0 mg/kg) in sufficient quantity for characterization by physicochemical techniques, including field-desorption mass spectrometry. This information together with results of chemical methylation of the compound proved that the major adduct formed between DNA and AFB1 in vivo is identical to that produced in vitro when AFB1 is incubated with DNA in the presence of a rat liver microsomal activating system. Quantitative studies of formation of this compound revealed a dose-ependent relationship between the level of its occurence in liver DNA and AFB1 doses over the range 0.125-1.0 mg/kg. Aflatoxin B1 (AFB1), a secondary fungal metabolite of several species of the genus Aspergillus, is acutely toxic to most animal species, although sensitivity varies widely. The rat, rainbow trout and duck are among the most susceptible to its toxic effects. AFB1 is also a potent hepatocarcinogen in these species (1) and is a potent mutagen in mammalian and bacterial cells (2-4). Epidemiological investigations in several human populations have revealed an association of increased incidences of hepatocellular carcinoma with increasing dietary contamination by AFB1 (5).Biological effects of AFB1 have been extensively studied in the rat. Acute doses of the toxin in this species produce both morphological and biochemical alterations primarily associated with the liver (6). Reversible inhibition of RNA synthesis has been demonstrated in vivo (7,8) and has been shown to be temporally associated with nucleolar segregation (9). DNA synthesis is also reversibly inhibited in normal (10) and partially hepatectomized (8, 11) animals following acute doses of the toxin.Investigations of various in vitro models have demonstrated the requirement for metabolic conversion of AFB1 to an active derivative which interacts covalently with DNA (12) and results in alterations of normal biochemical processes associated with it such as transcription and replication (8).Covalent binding of AFB1 to DNA in vitro is dependent on microsomal conversion of AFB1 to the reactive 2,3-exo-epoxide. Although this labile molecular species has not been isolated, much indirect evidence has accumulated to substantiate its transient existence (13,14). Covalent binding in vivo to nucleophilic atoms in proteins and nucleic acids is also thought to be mediated through metabolic activation to this reactive compound (15). Identification of the reactive sites in these macromolecules and the covalent compounds formed with AFB1 may provide a more complete understanding of its biological effects and provide further information on which to base hypotheses concerning the mechanisms underlying its carcinogenic properties.The nucleophilic sites of intera...